Pretreatment pregnancy testing under iPLEDGE still requires two tests in a medical setting before the first isotretinoin dose. iPLEDGE, the safety program for isotretinoin, shifts to updated rules on Nov.
15, 2026, so adult acne patients should plan tests around that date. The rules affect patients who can become pregnant prescribed the drug for severe recalcitrant nodular acne. According to the DailyMed/NLM isotretinoin label, the drug is reserved for severe nodular acne unresponsive to conventional therapy including systemic antibiotics.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What pretreatment testing still requires
- Why November 15 is the date to track
- What if you miss the 7-day window?
- What to confirm with prescriber and pharmacy
What pretreatment testing still requires
The process starts with a screening test when the prescriber decides to prescribe. A confirmatory test follows, and the pharmacy must dispense the drug within 7 days of the confirmatory specimen date, as described in the FDA advisory briefing document. All tests taken before the first dose in a course must occur in a medical setting such as a prescriber office, clinic, or laboratory.
The FDA Medical Organizations Communication Letter states that in-person setting rule, described in the FDA medical-setting letter. Ask where both specimens will be collected before you leave the first visit. Confirm how the office will date the confirmatory specimen and trigger the 7-day dispensing window.
Why November 15 is the date to track
FDA approved the shared-system iPLEDGE changes on Feb. 9, 2026, originally for effect about 180 days later around Aug. 8-9, 2026. Drugs.com reporting on the FDA action describes that original timeline in the FDA approval report.
Implementation later moved to Nov. 15, 2026. Lachman Consultants reporting on the FDA notice says the delay allows more system testing, reduces technical problems, and avoids interrupting access, detailed in the implementation delay notice. If you start treatment in fall 2026, ask whether your course falls under current or updated system steps. Keep your test dates, prescription date, and pickup deadline on one calendar.
What if you miss the 7-day window?
The 19-day lockout after missing the window is gone. A repeat test can occur immediately, according to the Journal of Dermatology Nurses' Association update in the dermatology nursing update. If you have not taken a first dose, that repeat test must still occur in a medical setting.
The rule differs from later in treatment, when prescribers may permit home tests with safeguards against falsified results, as reported by the National Community Pharmacists Association. Act quickly after a missed window and return to the office or lab for the new specimen. Do not substitute a home test for a pretreatment or repeat pretreatment test.
What to confirm with prescriber and pharmacy
Pharmacies must still obtain an iPLEDGE authorization before dispensing. They must also verify prescriber and patient enrollment, as described in the National Community Pharmacists Association June 2026 update.
The same update told authorized representatives to have pharmacists create personal accounts through the contact center. Home testing flexibility does not remove those pharmacy checks. Bring photo ID, your enrollment details, and a way to return quickly if retesting is needed.
- Confirm enrollment for you and the prescriber is active
- Ask which office, clinic, or lab will run each pretreatment test
- Ask how you will learn the confirmatory specimen date
- Confirm the pharmacy can obtain authorization before the 7-day deadline
You Might Also Like
- Planned Home Pregnancy Testing Under the 2026 iPLEDGE Changes: Timeline and Transition Questions for Adult Acne Patients
- Pretreatment Pregnancy Testing Under iPLEDGE in 2026: What the FDA Update Means for Adult Acne Patients
- Pretreatment Pregnancy Testing Under iPLEDGE in 2026: Common Transition Mistakes Parents of Teens With Severe Acne Can Avoid